Cure My Disease

Don't miss your cure!

 Log in / Sign up

A sharper look at the retina: new imaging technology may spot eye disease earlier

NCT ID NCT07725055

Knowledge-focused Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study is testing whether a specialized eye scanner called the MONA IV can capture clear, detailed images of the retina's tiny cells and blood vessels. Researchers will use it in people with conditions like glaucoma or age-related macular degeneration, as well as in healthy volunteers. The goal is to see if this tool can reliably detect subtle changes that might signal early disease or progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MONA IV adaptive-optics scanning ophthalmoscope
What this could lead to
If successful, this imaging method could enable earlier detection of retinal damage, potentially improving monitoring of diseases like glaucoma and macular degeneration.
What could go wrong
This is an observational imaging study, not a treatment trial. The images may not prove useful for clinical decisions, and results may not generalize beyond the specific devices used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 260 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients: * 100 subjects aged 10 to 79 years with a condition that may affect the inner retina (e.g., glaucoma, optic neuropathy, etc.) * 100 subjects aged 10 to 80 years with a condition that may affect the outer retina (e.g., AMD, retinitis pigmentosa, etc.) * Male or female * Covered by health insurance Healthy volunteers: * 30 subjects aged over 50 and under 80 * 30 subjects aged over 18 and under 50 * Male or female * Healthy subjects with no known condition that directly or indirectly affects the structure of the eye * Covered by health insurance Exclusion Criteria: For all subjects: * Inability to remain motionless on a standard ophthalmic chin rest. RETION\_Protocol\_v2.0 dated June 10, 2026\_IDRCB: 2026-A00324-47 Page 10 of 44 * Subjects taking medications or suffering from a medical condition that could interfere with the evaluations planned under the protocol; * Participants allergic to tropicamide in cases where pupil dilation is required. ☞ Wearing glasses or contact lenses to correct a refractive error is not considered an exclusion criterion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age related macular degeneration are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration glaucoma retinal disorder retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma associated with other ocular disorders Retina disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.